Story Stocks^®

Blackstone (BX) and TPG are reportedly in advanced discussions again to acquire Hologic (HOLX) for a price above $75 per share, valuing the women’s health-focused medical device maker at over $17 bln including debt, according to Bloomberg. The reported $75 per share offer represents a 7% premium to last Friday’s close, though the stock has already risen 30% since May, when Financial Times reported BX and TPG’s earlier $16 bln bid.

• HOLX develops diagnostic, surgical, and imaging products focused on women’s health, including mammography systems and molecular assays.
  
• The $75/share price equates to roughly 17.5x FY25 earnings, supported by strong profitability and $1.07 bln in trailing 12-month operating cash flow.
  
• Recent results have been mixed: Diagnostics grew 0.9%, Breast Health fell 6%, but Surgical rose 6.3%, led by the Gynesonics acquisition and international demand.
  
• A deal could ripple across the medical device sector, with peers like Boston Scientific (BSX), Stryker (SYK), and Zimmer Biomet (ZBH) potentially revalued higher amid renewed buyout interest.
  
• For BX, HOLX offers steady earnings, strong cash generation, and exposure to women’s health, a resilient niche with global growth potential.

Briefing.com Analyst Insight:

A buyout of HOLX by BX and TPG would be one of the largest medtech private equity deals in years, underscoring the sector’s appeal for investors seeking durable, cash-rich assets. The 17.5x FY25 multiple suggests confidence in HOLX’s profitability despite slower top-line growth. Strategically, the deal highlights how mature, cash-generative medical device firms are increasingly attractive private equity targets. For public peers, it could spur interest in further consolidation or asset spin-offs. While the premium is modest, the move reinforces private equity’s willingness to pay up for high-quality, recession-resistant healthcare names. If completed, the transaction could also pressure public medtech firms to accelerate innovation or restructuring efforts to avoid being viewed as stagnant buyout candidates.